These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 33858718)

  • 1. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
    Prymula R; Povey M; Brzostek J; Cabrnochova H; Chlibek R; Czajka H; Leviniene G; Man S; Neamtu M; Pazdiora P; Plesca D; Ruzkova R; Stefkovicova M; Usonis V; Verdanova D; Wysocki J; Casabona G; Habib MA
    Vaccine; 2021 May; 39(19):2643-2651. PubMed ID: 33858718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial.
    Povey M; Henry O; Riise Bergsaker MA; Chlibek R; Esposito S; Flodmark CE; Gothefors L; Man S; Silfverdal SA; Štefkovičová M; Usonis V; Wysocki J; Gillard P; Prymula R
    Lancet Infect Dis; 2019 Mar; 19(3):287-297. PubMed ID: 30765242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial.
    Prymula R; Bergsaker MR; Esposito S; Gothefors L; Man S; Snegova N; Štefkovičova M; Usonis V; Wysocki J; Douha M; Vassilev V; Nicholson O; Innis BL; Willems P
    Lancet; 2014 Apr; 383(9925):1313-1324. PubMed ID: 24485548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
    Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life.
    Henry O; Brzostek J; Czajka H; Leviniene G; Reshetko O; Gasparini R; Pazdiora P; Plesca D; Desole MG; Kevalas R; Gabutti G; Povey M; Innis B
    Vaccine; 2018 Jan; 36(3):381-387. PubMed ID: 29224964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of early vaccination with two doses of a combined measles-mumps-rubella-varicella vaccine in healthy Indian children from 9 months of age: a phase III, randomised, non-inferiority trial.
    Lalwani S; Chatterjee S; Balasubramanian S; Bavdekar A; Mehta S; Datta S; Povey M; Henry O
    BMJ Open; 2015 Sep; 5(9):e007202. PubMed ID: 26362659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children.
    Namazova-Baranova L; Habib MA; Povey M; Efendieva K; Fedorova O; Fedoseenko M; Ivleva T; Kovshirina Y; Levina J; Lyamin A; Ogorodova L; Reshetko O; Romanenko V; Ryzhenkova I; Sidorenko I; Yakovlev Y; Zhestkov A; Tatochenko V; Scherbakov M; Shpeer EL; Casabona G;
    Hum Vaccin Immunother; 2022 Jan; 18(1):1959148. PubMed ID: 34435933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
    Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
    Casabona G; Berton O; Singh T; Knuf M; Bonanni P
    Expert Rev Vaccines; 2023; 22(1):764-776. PubMed ID: 37642012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
    Marshall GS; Senders SD; Shepard J; Twiggs JD; Gardner J; Hille D; Hartzel J; Valenzuela R; Stek JE; Helmond FA
    Hum Vaccin Immunother; 2016 Aug; 12(8):2188-2196. PubMed ID: 27149048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.